Evidence map›Paper›PMID 39857177›Full record

ArticleHealthcare (Basel, Switzerland)2025

Clinical Assessment of Puressentiel

Nicolas Barizien, Perrine Capron, Thomas Mamou, Françoise Louni, Roland Krzentowski, Paul Fogel

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04736563 (Evaluation of the Antalgic Effect of Puressentiel Joints and Muscles - Gel with14 Essential Oils on Joint Pain of the Knee), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04736563 naunknown statusnot on this map

Evaluation of the Antalgic Effect of Puressentiel Joints and Muscles - Gel with14 Essential Oils on Joint Pain of the Knee

TypeinterventionalSponsorMarco PacchioniRan2021 to 2021Enrolled40ConditionsPain, Joint PainArmsJoint and muscle gel Puressentiel
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicolas BarizienService de Réadaptation Fonctionnelle, Hôpital Foch, 92150 Suresnes, France.ORCID 0009-0002-2419-7701
Perrine CapronClinique du Sport, 134 Bd Saint Marcel, 75005 Paris, France.
Thomas MamouInstitut Médico-Sportif Préfontaine, 55 Rue Cortambert, 75016 Paris, France.
Françoise LouniService des Maladies Infectieuses, Hôpital Bichat, 75018 Paris, France.
Roland KrzentowskiComité Départemental Olympique de Paris, 75013 Paris, France.
Paul FogelForvisMazars, 94200 Courbevoie, France.ORCID 0000-0002-5398-6622

Funding

Laboratoire Puressentiel NCT04736563
6 · The paper itself

Abstract

introductionKnee osteoarthritis (OA) is a degenerative joint disease that affects millions globally, causing chronic pain and limited mobility. Pharmacological treatments for OA-related knee pain come with risks, making alternative or complementary therapies attractive. This post-market trial evaluates the efficacy of Puressentiel

methodIn this 12-week open-label trial (NCT04736563), participants aged 45-90 with OA-related knee pain applied Puressentiel

resultsSignificant improvements in WOMAC and VAS scores were observed during treatment (

conclusionPuressentiel

Indexed as

aromatherapyessential oilsknee osteoarthritispainPuressentiel® Muscles and Joints geltopical treatmentWOMAC

Identifiers

PMID39857177
PMCPMC11765122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.